WALTHAM, Mass., Jan. 6 /PRNewswire/ -- ImmuLogic Pharmaceutical
Corporation (Nasdaq: IMUL) today announced the filing of an investigational
new drug (IND) application with the Food and Drug Administration to initiate
human clinical trials for a multiple sclerosis peptide therapeutic.
    "This IND was filed in preparation for a phase I trial we plan to initiate
in the second quarter of 1997, following the completion of final manufacturing
processes for the clinical grade product to be used in the trial," said Joseph
Marr, MD, Acting President and Chief Executive Officer of ImmuLogic
Pharmaceutical Corporation.  "This IND filing is our first step in expanding
the clinical application of our core technology of tolerance induction beyond
allergy and into the autoimmune disease arena.  The autoimmune patient groups
have a significant need for novel therapeutics that we hope to address with
products from our program."
    Although significant advances in the therapeutic management of multiple
sclerosis have been made, there is an additional need for products which
specifically address the underlying cause of the disease.  The ImmuLogic
therapeutic is aimed at turning off the T cells which trigger the inflammatory
response that destroys the myelin sheath surrounding nerves.  ImmuLogic's
multiple sclerosis peptide therapeutic consists of myelin basic protein
peptides administered by subcutaneous injection.  The company is developing
its multiple sclerosis program in collaboration with Schering AG, Germany, a
world leader in the multiple sclerosis disease management field.
    ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Massachusetts, with the primary goal of developing peptide
therapeutics to treat allergies and autoimmine diseases.  The Company also is
developing a poison ivy/poison oak therapeutic and a vaccine to treat cocaine
abuse.

Link to this page: